👇will change my practice today RDBPCT, N= 124 #gastric #HPB #lung #cancer Journal of Clinical Oncology 📌 Olanzapine 2.5mg/day ⬆️ appetite, weight and QoL ⭐️ simple inexpensive intervention for a common and difficult problem for our pts with #GIcancer Congrats to the study team 🇮🇳 🙏

Publication dans JAMA Network d'une vaste enquête sur l'état psychologique des hospitalo-universitaires 🇫🇷 Symptômes de : - Burn Out sévère 40% - Idées suicidaires 14% 41% des MCUPH/29% des PUPH déclarent envisager un changement de carrières ! On attend quoi pour réagir ???

🔥Zolbetuximab + mFOLFOX6 in CLDN18.2+, HER2- gastric or gastro-oesophageal junction adenocarcinoma The Lancet doi.org/10.1016/S0140-… 🔎SPOTLIGHT phs-III 💪mPFS: 10.6 vs 8.7, mOS: 18.2 vs 15.5 mo, no increase in ORR 🤔13% CPS>5 -> role of ICI? ✅new🎯in GC! More 💊to come...

What a GREAT opportunity to discuss colorectal cancer with young oncologists from all over Europe !! Huge huge thanks to Andres Cervantes Erika Martinelli @DucreuxMichel Jenny Seligmann Myriam Chalabi ! And thx ESMO - Eur. Oncology :)

#Goosebumps #EV302 #ESMO23 Took 3 decades but a new SOC in 1L bladder cancer !!!!!! ⁦Tom Powles⁩ EV+Pembro irrespective…..WOW! 🤩

Historical moment for GU oncology. Tom Powles brilliantly presents the results of the EV-302 phase 3 trial, showing a doubling of OS for patients with mUC receiving 1L enfortumab vedotin+pembro vs SoC platinum-based chemo. ADCs keep shining and improving outcomes! #ESMO23

Enfortumab vedotin & Pembrolizumab improving PFS & OS by 55% & 53% respectively compared to platinum based chemo in 1st line UC (+avelumab in 30%). Chemo has not been beaten before (despite multiple efforts). RR and CR of 68% & 29% is hard to beat. DOR not reached (1/3)#ESMO2023

Wonderful presentation of impressive data in patients with mUC by Tom Powles Mid-presentation 👏 after seeing PFS and OS data, HR 0.45 and 0.47 respectively! My goosebumps are not going away! #ESMO23 ESMO - Eur. Oncology OncoAlert van der Heijden Lab

Come visit our poster 1450P ESMO - Eur. Oncology >1500pts from IMpower130+150 (L1 nsq-NSCLC) : - Only pts with LiverMets have an OS benefit of bevacizumab+CTIO over CTIO. - HR 0.43 !! - Does Bev reverse LiverMet immunosuppressive TME ? Benjamin Besse Edouard Auclin Laura Mezquita

Our work on senescent CD8 T cells (T8sen) in patients with aNSCLC is out in Science Advances ! Congratulations mar Chaput Nathalie Benjamin Besse for leading this project ! 👉 science.org/doi/10.1126/sc…

First results of the CM8HW are out! Nivo/ipi vs chemo in 1st line dMMR mCRC. We knew it would be positive, but wow 🤯 HR 0.21 for PFS and + across all subgroups. No crossing of the curves! Toxicity very manageable (don’t be scared of low dose ipi1).

Early Morning Immune Checkpoint Blockade and Overall Survival of Patie... sciencedirect.com/science/articl…

KRAS - the most commonly mutated oncogene in cancer. Nice slide to show the incidence of various types of KRas mutations in various cancers. As of today only , G12C is druggable ESMO - Eur. Oncology #ESMOGI24

Thrilled to announce our poster on early-onset CCA won Best Poster at #ESMOGI24! Congrats to @AnthoTurpin and the entire Vall d’Hebron Institute of Oncology (VHIO) and Gustave Roussy collaboration group. Very proud to be part of this! ESMO - Eur. Oncology Teresa Macarulla TIAN TIAN @DucreuxMichel #ESMOAmbassadors

#Podcast 2️⃣ Nouvel épisode consacré au cancer gastrique sur la place de l’immunothérapie avec le Dr Anthony Turpin, oncologue au CHU de Lille 📲 À retrouver dès maintenant dans votre [espace Pro] sur #OncoClic #oncology #gastric #pd1 #immunotherapy

Une étude menée entre autres par des scientifiques de l’#Inserm révèle comment le #diabète de type 2 peut provoquer des changements épigénétiques menant au #cancer du pancréas. Lire le communiqué : presse.inserm.fr/diabete-decouv…

L'AFUF vous présente son nouveau conseil d'administration ! 🚀 Une nouvelle mandature débute aujourd'hui autour d'un bureau élargi avec Denis Séguier Président, Gaëlle Margue Vice-présidente, Peyrottes Arthur Secrétaire et Stephan Lévy Trésorier. #CFU2024 Association Française d'Urologie - AFU

IL-6R blockade to uncouple toxicité ans efficace in ICB-treated patients ? Our editorial Annals of Oncology 👇 Thank you to coauthors !!

Only 25 % of our 🇫🇷 residents are interested in #Academics. Fantastic talk from Denis Séguier. Nothing more rewarding to see your #trainees shinning on the stage. #BAU2024 Association Française d'Urologie - AFU

ESOPEC trial - Game changer for resectable esophageal adenocarcinoma Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Esophageal Cancer | New England Journal of Medicine nejm.org/doi/full/10.10…